Phase I Study of FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors, including Pancreatic Cancer
Summary
The purpose of this phase I study is to evaluate the safety and tolerability of FT536 monotherapy in combination with solid tumors, including pancreatic cancer.
General Information
NCT#: NCT05395052
Study ID: FT536-101
Trial Phase: Phase I
Trial Sponsor: Fate Therapeutics
Therapies Used in This Trial: FT536